Saturday, November 16, 2024 7:37:52 PM
“Around 5 years ago Lyin' Les Goldman used disgraced blogger Chris LaCoursiere to pump an imminent contract with BP which would include an upfront payment and contingent milestone payments. The internet army (see main culprits above) ran with it for weeks. Finally, the news was released in which Merck had agreed to supply Keytruda free of charge for an upcoming combo trial. No cash and no contingent payments (of course the internet army proclaimed this as great news because Merck was just waiting to buy NWBO, why would they throw money at a takeover).”
- I wouldn’t be surprised if we see a similar contract. No upfront payment, just free drug from big pharma in the combo trial. Otherwise no reason to pump this in advance in the 10Q. Besides big pharma wouldn’t allow this as it could potentially open them up for insider trading charges, risk disruption from a competitor, etc.
A quick question for you - how did NWBO fund this trial? And which combo trial was this? I am not aware of any combo trial where NWBO is involved in terms of sponsor.
- I wouldn’t be surprised if we see a similar contract. No upfront payment, just free drug from big pharma in the combo trial. Otherwise no reason to pump this in advance in the 10Q. Besides big pharma wouldn’t allow this as it could potentially open them up for insider trading charges, risk disruption from a competitor, etc.
A quick question for you - how did NWBO fund this trial? And which combo trial was this? I am not aware of any combo trial where NWBO is involved in terms of sponsor.
Recent NWBO News
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 04/21/2026 04:15:08 AM
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 04/16/2026 09:25:30 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/07/2026 04:30:50 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/31/2026 09:04:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/15/2026 10:06:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/02/2026 10:14:59 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/28/2025 09:43:27 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/25/2025 10:23:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/20/2025 09:26:03 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 11/19/2025 09:15:48 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:44:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/31/2025 04:29:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2025 08:40:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/24/2025 04:28:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/14/2025 06:22:26 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2025 09:00:38 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 07/01/2025 09:04:38 PM
